Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control

Epilepsia

Volumn 51, Issue 11, 2010, Pages 2231-2240

  Schmitz, Bettina ^a   Montouris, Georgia ^b   Caleo, Sue ^d   Schäuble, Barbara ^c  

^a VIVANTES HOSPITAL   (Germany)

^b BOSTON MEDICAL CENTER   (United States)

^c Medical Affairs   (Germany)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; MOOD STABILIZER; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; RETIGABINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABNORMAL THINKING; AFFECTIVE PSYCHOSIS; AGGRESSION; AGITATION; ANTICONVULSANT THERAPY; ANXIETY; APLASTIC ANEMIA; ATTENTION DISTURBANCE; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHASIA; EMOTIONAL DISORDER; FLUENCY DISORDER; FOCAL EPILEPSY; HOSTILITY; HUMAN; IMPOTENCE; IRRITABILITY; LIVER TOXICITY; MENTAL CONCENTRATION; MENTAL DETERIORATION; MENTAL INSTABILITY; MONOTHERAPY; MOOD; MORBIDITY; NERVOUSNESS; PARTIAL ONSET EPILEPSY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SUICIDE ATTEMPT; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; QUALITY OF LIFE; RISK FACTORS;

EID: 78349274991     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02759.x     Document Type: Review

References (63)

1. Abou-Khalil B,. (2005) Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf 28: 871 - 890.
2. Aldenkamp A, Mulder O, Overweg J,. (1997) Cognitive effects of lamotrigine as first-line add-on in patients with localization-related (partial) epilepsy. J Epilepsy 10: 117 - 121.
3. Bastiampillai TJ, Reid CE, Dhillon R, (2010) The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder. J Psychopharmacol February 8 [Epub ahead of print].
4. Baulac M, Leppik I,. (2007) Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 75: 75 - 83.
5. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD,. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308 - 1317.
6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61: 1 - 48.
7. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73: 1 - 52.
8. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojrvi J,. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67: 400 - 406.
9. De Boer HM, Mula M, Sander JW,. (2008) The global burden and stigma of epilepsy. Epilepsy Behav 12: 540 - 546.
10. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, De Krom M, Aldenkamp AP,. (2008) Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17: 19 - 26.
11. Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M, Schellekens A, De Krom M, Aldenkamp AP,. (2009) The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure 18: 327 - 331.
12. Brodie MJ,. (2004) Zonisamide clinical trials: European experience. Seizure 13: 66 - 70.
13. Baulac M, Brodie MJ, Elger CE, Krakow K, Stockis A, Meyvisch P, Falter U,. (2007) Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 48: 589 - 592.
14. Carreno M, Maestro I, Molins A, Donaire A, Falip M, Becerra JL, Castillo J,. (2007) Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 16: 709 - 712.
15. Chaisewikul R, Privitera MD, Hutton JL, Marson AG, (2001) Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev 1:CD001901.
16. Cho YJ, Heo K, Kim WJ, Jang SH, Jung YH, Ye BS, Song DB, In LB,. (2009) Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 50: 1910 - 1919.
17. Cramer JA, Arrigo C, Van Hammee G, Bromfield EB,. (2000) Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res 41: 29 - 38.
18. Cramer J, Ryan J, Chang J, Sommerville K,. (2001) The short-term impact of adjunctive tiagabine on health-related quality of life. Epilepsia 42: 70 - 75.
19. Cramer JA, De R, Devinsky O, Edrich P, Trimble MR,. (2003) A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 4: 124 - 132.
20. Duncan S, Talbot A, Sheldrick R, Caswell H,. (2009) Erectile function, sexual desire, and psychological well-being in men with epilepsy. Epilepsy Behav 15: 351 - 357.
21. Faught E, Matsuo F, Schachter S, Messenheimer J, Womble G,. (2004) Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav 5: 31 - 36.
22. Finocchi C, Villani V, Casucci G,. (2010) Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence. Neurol Sci 31: 95 - 98.
23. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden C, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer J, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA,. (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62: 1261 - 1273.
24. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C,. (2005) Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6: 373 - 381.
25. Gidal B, Sheth R, Magnus L, Herbeuval A,. (2003) Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 56: 121 - 126.
26. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H,. (2004) Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62: 23 - 27.
27. Gil-Nagel A, Zaccara G, Baldinetti F, Leon T,. (2009) Add-on treatment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. Seizure 18: 184 - 192.
28. Hamandi K, Sander J,. (2006) Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 15: 73 - 78.
29. Hemming K, Maguire MJ, Hutton JL, Marson AG, (2008) Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 3:CD007302.
30. Hesdorffer DC, Kanner AM,. (2009) The FDA alert on suicidality and antiepileptic drugs: fire or false alarm? Epilepsia, 50: 978 - 986.
31. Holtkamp M, Weissinger F, Meierkord H,. (2005) Erectile dysfunction with topiramate. Epilepsia 46: 166 - 167.
32. Johannessen Landmark C, Johannessen SI,. (2008) Pharmacological management of epilepsy: recent advances and future prospects. Drugs, 68: 1925 - 1939.
33. Kaiser S, Selai CE, Trimble MR,. (2002) Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. Seizure 11: 356 - 360.
34. Kalviainen R,. (2001) Long-term safety of tiagabine. Epilepsia 42: 46 - 48.
35. Kanner AM,. (2009) Suicidality and epilepsy: a complex relationship that remains misunderstood and underestimated [Abstract]. Epilepsy Curr 9: 63 - 66.
36. Kuba R, Pohanka M, Zakopcan J, Novotna I, Rektor I,. (2006) Sexual dysfunctions and blood hormonal profile in men with focal epilepsy. Epilepsia 47: 2135 - 2140.
37. Kwan P, Brodie MJ,. (2001) Effectiveness of first antiepileptic drug. Epilepsia 42: 1255 - 1260.
38. Labiner DM, Ettinger AB, Fakhoury TA, Chung SS, Shneker B, Tatum Iv WO, Mitchell MJ, Vuong A, Hammer AE, Messenheimer JA,. (2009) Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 50: 434 - 442.
39. LaRoche SM, Helmers SL,. (2004) The new antiepileptic drugs: Clinical applications. JAMA 291: 615 - 620.
40. Latini G, Verrotti A, Manco R, Scardapane A, Del V, Chiarelli F,. (2008) Topiramate: Its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 8: 10 - 23.
41. Leppik IE, Gram L, Deaton R, Sommerville KW,. (1999) Safety of tiagabine: summary of 53 trials. Epilepsy Res 33: 235 - 246.
42. Levenson JL,. (2008) Psychiatric issues in neurology, part 3: Epilepsy. Primary Psychiatry 15: 21 - 25.
43. Luef G, Kramer G, Stefan H,. (2009)) Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand 119: 94 - 99.
44. Marino SE, Meador KJ, Loring DW, Okun MS, Fernandez HH, Fessler AJ, Kustra RP, Miller JM, Ray PG, Roy A, Schoenberg MR, Vahle VJ, Werz MA,. (2009) Subjective perception of cognition is related to mood and not performance. Epilepsy Behav 14: 459 - 464.
45. McCormack PL, Robinson DM,. (2009) Eslicarbazepine acetate. CNS Drugs 23: 71 - 79.
46. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R,. (2003) Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60: 1483 - 1488.
47. Mintzer S,. (2010) Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 23: 164 - 169.
48. Mula M, Sander JW,. (2007) Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30: 555 - 567.
49. Mula M, Trimble MR, Sander JW,. (2007) Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 48: 2322 - 2326.
50. Otoul C, Arrigo C, Van R, French J,. (2005) Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28: 72 - 78.
51. Piazzini A, Chifari R, Canevini M, Turner K, Fontana S, Canger R,. (2006) Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res 68: 181 - 188.
52. Ramaratnam S, Marson AG, Baker GA,. (2001) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001909.
53. Ryvlin P, Perucca E, Rheims S,. (2008) Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat 4: 1211 - 1224.
54. Selai C, Bannister D, Trimble M,. (2005) Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 46: 50 - 57.
55. SMPC of Sabril (vigabatrin). (2009), Accessed March 5, 2010.
56. Somerville E, McLaughlin D, Robinson M, Berkovic S,. (2007) Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients. Epilepsy Behav 11: 338 - 342.
57. Steinhoff B, Somerville E, Van P, Ryvlin P, Schelstraete I,. (2007) The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 76: 6 - 14.
58. Sunmonu TA, Komolafe MA, Ogunrin AO, Ogunniyi A,. (2009) Cognitive assessment in patients with epilepsy using the Community Screening Interview for Dementia. Epilepsy Behav 14: 535 - 539.
59. Tracy JI, Dechant V, Sperling MR, Cho R, Glosser D,. (2007) The association of mood with quality of life ratings in epilepsy. Neurology 68: 1101 - 1107.
60. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics. (May 21, 2008) Statistical review and evaluation: antiepileptic drugs and suicidality. Available at:, Accessed June 6, 2010.
61. Valentin A, Moran N, Hadden R, Oakes A, Elwes R, Delamont R, Mullatti N, Nashef L,. (2009) Pregabalin as adjunctive therapy for partial epilepsy: an audit study in 96 patients from the South East of England. Seizure 18: 450 - 452.
62. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, Meara S, Sculpher M, Drummond M, Forbes C,. (2005) Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 9: 1 - 157.
63. Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D,. (2008) Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 12: 305 - 310.